High Drug Costs and Copay Assistance: A Patient’s Struggle

Over the course of 2025, Jayant Mishra of Mission Viejo, California, experienced the challenges many Americans face when navigating the high cost of prescription drugs. Diagnosed with psoriatic arthritis, Mishra found initial relief with Otezla, but the assistance he received through a copay card proved temporary, leaving him facing substantial out-of-pocket expenses.

The Diagnosis and Initial Relief

Mishra’s journey began with the development of scaly, itchy red patches on his skin, followed by pain and swelling in his hands, impacting his ability to work at a bank. A rheumatologist diagnosed him with psoriatic arthritis and recommended Otezla, a medication designed to manage the autoimmune disease. Initially hesitant due to the drug’s high list price – around $5,000 for a 30-day supply, according to News-Medical.net – Mishra eventually agreed to try a starter pack provided by the manufacturer, Amgen.

The Copay Card and Unexpected Costs

After Otezla proved effective, Mishra’s rheumatologist secured insurance approval and enrolled him in Amgen’s copayment assistance program. He was initially led to believe the card would cover his costs for a year. However, the reality proved far more complex. His insurance provider, UnitedHealthcare, through its pharmacy benefit manager OptumRx, did not negotiate a significant discount, covering only $308.34 of the $5,253.85 charge for a 30-day supply. This depleted his $9,450 copay card after just two months, leaving him with a $441.02 bill for the second month’s supply.

The Tug-of-War Between Drug Manufacturers and Insurers

Experts describe copay assistance programs as part of a complex interplay between drug manufacturers and insurers. Aaron Kesselheim, a professor of medicine at Harvard Medical School, notes that the value of these cards is becoming increasingly unpredictable as insurers attempt to restrict their use. Many insurance plans do not count copay assistance towards a patient’s deductible, and patients using these cards can end up paying the full list price rather than a negotiated rate. As KFF Health News reports, this can leave patients reliant on drugs they ultimately cannot afford.

Manufacturer Incentives and Generic Alternatives

Drug manufacturers offer copay assistance to encourage patients to choose brand-name drugs, even when cheaper alternatives exist. Fiona Scott Morton, an economist at the Yale School of Management, suggests this discourages patients from discussing more affordable options, like generic drugs, with their doctors. Although a generic version of Otezla was approved in 2021, Amgen has actively pursued legal action to delay its availability in the U.S., maintaining patent protection until 2028. Generic versions are available in other countries, such as Canada, at significantly lower prices.

Mishra’s Experience and the Path Forward

Mishra utilized his health savings account (HSA) to cover the remaining costs, but faced continued uncertainty about future expenses. He rationed his medication to stretch his supply, experiencing a return of symptoms. Despite his financial ability to manage the costs, Mishra expressed frustration with the lack of transparency and the unexpected financial burden. He ultimately learned that selecting a different health plan in 2026 could have provided better coverage for Otezla, with a $100 monthly copay, albeit with a higher premium.

Key Takeaways

• Copay cards do not guarantee predictable or long-term cost savings.
• Insurance plans may not count copay assistance towards deductibles.
• Patients should discuss all medication options, including generics, with their doctors.
• Consider prescription drug coverage when selecting a health plan.

Mishra’s case highlights the challenges patients face in navigating the complex landscape of prescription drug pricing and assistance programs. As the debate over healthcare affordability continues, understanding these intricacies is crucial for both patients and policymakers.